BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 182 filers reported holding BRIDGEBIO PHARMA INC in Q1 2022. The put-call ratio across all filers is 0.50 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $424 | -11.7% | 16,095 | -42.3% | 0.03% | -15.8% |
| Q2 2023 | $480 | +90.5% | 27,916 | +83.5% | 0.04% | +111.1% |
| Q1 2023 | $252 | -2.3% | 15,216 | -55.0% | 0.02% | -14.3% |
| Q4 2022 | $258 | -99.9% | 33,826 | +1.4% | 0.02% | -32.3% |
| Q3 2022 | $331,000 | -29.9% | 33,350 | -35.8% | 0.03% | -27.9% |
| Q2 2022 | $472,000 | +48.9% | 51,948 | +66.2% | 0.04% | +330.0% |
| Q1 2022 | $317,000 | – | 31,264 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 6,068,125 | $100,609,513 | 48.41% |
| Kohlberg Kravis Roberts & Co. L.P. | 31,060,971 | $514,990,899 | 15.50% |
| M28 Capital Management LP | 304,700 | $5,051,926 | 5.71% |
| Cormorant Asset Management, LP | 4,557,414 | $75,562 | 4.98% |
| Octagon Capital Advisors LP | 1,338,160 | $22,186,693 | 3.19% |
| Ikarian Capital, LLC | 594,686 | $9,859,894 | 2.24% |
| Affinity Asset Advisors, LLC | 389,800 | $6,462,884 | 2.13% |
| VIKING GLOBAL INVESTORS LP | 26,620,991 | $441,376,031 | 2.07% |
| Ikarian Capital, LLC | 549,600 | $9,112,368 | 2.07% |
| Affinity Asset Advisors, LLC | 320,000 | $5,305,600 | 1.75% |